Victory Capital Management’s Theriva Biologics TOVX Stock Holding History

Victory Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-88	Closed	-$5K	–	2774
2022 Q2	$5K	Sell	88 -1	-1%	-$57	﹤0.01%	2680
2022 Q1	$5K	Buy	89 +13	+17%	+$886	﹤0.01%	2705
2021 Q4	$5K	Sell	76 -2	-3%	-$189	﹤0.01%	2757
2021 Q3	$9K	Sell	78 -4	-5%	-$498	﹤0.01%	2763
2021 Q2	$12K	Sell	82 -1	-1%	-$143	﹤0.01%	2727
2021 Q1	$14K	Buy	+83	New	+$16.4K	﹤0.01%	2734
2020 Q2	–	Sell	-23	Closed	-$2K	–	3224
2020 Q1	$2K	Buy	+23	New	+$2.62K	﹤0.01%	3679
2019 Q4	–	Sell	-11	Closed	-$1K	–	3230
2019 Q3	$1K	Buy	+11	New	+$1.33K	﹤0.01%	3721

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Victory Capital Management's TOVX Position: Q3 2022 in Review

Victory Capital Management sold out of Theriva Biologics (TOVX) in Q3 2022, closing a stake of 88 shares — an estimated $5K sold.

Victory Capital Management first reported a position in TOVX in Q3 2019 and held it in 8 quarters. The position peaked at $14K in Q1 2021. 24 funds tracked by Wall St. Rank hold TOVX as of Q3 2022.

Victory Capital Management reported no remaining Theriva Biologics position as of Q3 2022 after selling out during the quarter.
Victory Capital Management sold 88 Theriva Biologics shares in Q3 2022, an estimated $5K.
Victory Capital Management first reported a position in Theriva Biologics in Q3 2019 and held it in 8 quarters.
Victory Capital Management's Theriva Biologics position peaked at $14K in Q1 2021.
24 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2022.

Based on Victory Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.